173 related articles for article (PubMed ID: 7998111)
41. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.
Kuhn C; Weiner HL
Immunotherapy; 2016 Jul; 8(8):889-906. PubMed ID: 27161438
[TBL] [Abstract][Full Text] [Related]
42. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
Bach JF
Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
[No Abstract] [Full Text] [Related]
43. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
44. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
[TBL] [Abstract][Full Text] [Related]
46. Immunosuppressive therapy of autoimmune diseases.
Bach JF
Immunol Today; 1993 Jun; 14(6):322-6. PubMed ID: 8104411
[TBL] [Abstract][Full Text] [Related]
47. Long-term functional xenograft tolerance after intrathymic islet transplantation (Lewis rat-->B6 mouse).
Zeng Y; Bluestone JA; Ildstad ST; Torres MA; Montag AG; Thistlethwaite RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):438-9. PubMed ID: 8438368
[No Abstract] [Full Text] [Related]
48. Anti-class II antibody treatment in autoimmune diseases.
Boitard C
Immunol Ser; 1993; 59():279-93. PubMed ID: 8461393
[No Abstract] [Full Text] [Related]
49. [Muromonab CD3--the first monoclonal antibody used in humans].
Makulska-Nowak E
Pol Tyg Lek; 1993 Dec 13-27; 48(50-52):857-9. PubMed ID: 7971509
[No Abstract] [Full Text] [Related]
50. Clinical studies. Trying to reset the clock on type 1 diabetes.
Couzin-Frankel J
Science; 2011 Aug; 333(6044):819-21. PubMed ID: 21835995
[No Abstract] [Full Text] [Related]
51. T cell targeted immunotherapy for autoimmune disease.
Lee E; Sinha AA
Autoimmunity; 2005 Dec; 38(8):577-96. PubMed ID: 16390811
[TBL] [Abstract][Full Text] [Related]
52. The effect of CD3-specific monoclonal antibody on treating experimental autoimmune myasthenia gravis.
Xu RN; Wang JN; Chen GJ; Han GC; Wang RX; Shen BF; Li Y
Cell Mol Immunol; 2005 Dec; 2(6):461-5. PubMed ID: 16426497
[TBL] [Abstract][Full Text] [Related]
53. -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?
Ballow M
J Allergy Clin Immunol; 2005 Oct; 116(4):738-43. PubMed ID: 16210044
[No Abstract] [Full Text] [Related]
54. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
Murphy WJ; Conlon KC; Sayers TJ; Wiltrout RH; Back TC; Ortaldo JR; Longo DL
J Immunol; 1993 Apr; 150(8 Pt 1):3634-42. PubMed ID: 8468492
[TBL] [Abstract][Full Text] [Related]
55. Anti-T cell monoclonal antibodies for immunosuppression in xenotransplantation of fetal pig pancreas in NOD mice.
Mandel TE; Koulmanda M
Transplant Proc; 1993 Feb; 25(1 Pt 1):796-7. PubMed ID: 8438485
[No Abstract] [Full Text] [Related]
56. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
57. In vivo use of OKT3: main issues for the monitoring of treated patients.
Chatenoud L; Ferran C; Bach JF
Transplant Proc; 1990 Dec; 22(6):2605-8. PubMed ID: 2124743
[No Abstract] [Full Text] [Related]
58. Prolongation of skin xenograft survival with concomitant donor bone marrow transplantation.
Jeyarajah DR; Schmeisser FS; Kadakia RA; Thistlethwaite JR
Transplant Proc; 1994 Jun; 26(3):1201-2. PubMed ID: 8029886
[No Abstract] [Full Text] [Related]
59. Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation.
Udagawa T; Woodside DG; McIntyre BW
J Immunol; 1996 Sep; 157(5):1965-72. PubMed ID: 8757316
[TBL] [Abstract][Full Text] [Related]
60. Macrophage inflammatory protein-1 alpha rapidly modulates its receptors and inhibits the anti-CD3 mAb-mediated proliferation of T lymphocytes.
Zhou Z; Kim YJ; Pollok K; Hurtado J; Lee JK; Broxmeyer HE; Kwon BS
J Immunol; 1993 Oct; 151(8):4333-41. PubMed ID: 8409405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
